Kazia Therapeutics: CFO Resigns, New Financial Officer Appointed
Ticker: KZIA · Form: 6-K · Filed: Jan 12, 2024 · CIK: 1075880
Complexity: simple
Sentiment: neutral
Topics: management-change, CFO-resignation, executive-appointment
TL;DR
**Kazia Therapeutics just swapped out its CFO, bringing in Gabrielle Heaton for AUD $248,000 annually.**
AI Summary
Kazia Therapeutics Limited announced significant leadership changes, with Karen Krumeich resigning as Chief Financial Officer on January 8, 2024. The company quickly appointed Gabrielle Heaton as Principal Accounting Officer and Principal Financial Officer, effective January 15, 2024, with an annual base compensation of AUD $248,000. This matters to investors because changes in key financial leadership can impact a company's strategic direction and financial reporting stability, even if, as stated, Ms. Krumeich's resignation was not due to disagreements.
Why It Matters
Changes in top financial leadership can signal shifts in company strategy or operations, potentially affecting investor confidence and the company's financial trajectory.
Risk Assessment
Risk Level: medium — While the company states the CFO's resignation wasn't due to disagreements, any change in key financial leadership introduces a period of potential instability and transition risk.
Analyst Insight
Investors should monitor Kazia Therapeutics' upcoming financial reports and any further announcements regarding its financial strategy to assess the impact of this leadership transition.
Key Numbers
- AUD $248,000 — Gabrielle Heaton's annual base compensation (This is the salary for the new Principal Accounting Officer and Principal Financial Officer.)
- January 8, 2024 — Date of CFO resignation notice (Marks the start of the leadership transition period.)
- January 11, 2024 — Date of new officer appointment (Shows the swift action taken by the Board to fill the financial leadership role.)
- January 15, 2024 — Effective date of new officer's role (Indicates when Gabrielle Heaton officially assumes her new responsibilities.)
Key Players & Entities
- Karen Krumeich (person) — resigning Chief Financial Officer of Kazia Therapeutics Limited
- Gabrielle Heaton (person) — appointed Principal Accounting Officer and Principal Financial Officer of Kazia Therapeutics Limited
- Kazia Therapeutics Limited (company) — the registrant making the filing
- AUD $248,000 (dollar_amount) — Gabrielle Heaton's annual base compensation
Forward-Looking Statements
- Kazia Therapeutics will maintain stable financial reporting despite the leadership change. (Kazia Therapeutics Limited) — medium confidence, target: Q1 2024 earnings report
- Gabrielle Heaton will bring new strategic insights to the financial operations. (Gabrielle Heaton) — low confidence, target: Next 12 months
FAQ
Who resigned from Kazia Therapeutics Limited and what was their role?
Karen Krumeich resigned as the Chief Financial Officer of Kazia Therapeutics Limited, with notice received on January 8, 2024.
When was the new Principal Accounting Officer and Principal Financial Officer appointed?
Gabrielle Heaton was appointed as Principal Accounting Officer and Principal Financial Officer by the Company's Board of Directors on January 11, 2024.
What is the annual base compensation for the newly appointed financial officer?
Gabrielle Heaton's annual base compensation will be AUD $248,000.
Was the resignation of the former CFO due to any disagreements with the company?
No, the filing explicitly states that Ms. Krumeich's resignation is not the result of any disagreement between her and the Company, its management or board of directors, or related to the Company's operations, policies or practices.
What will be Karen Krumeich's role after her resignation as CFO?
Ms. Krumeich will remain with the Company in an advisory role for a mutually agreed period to support the transition.
Filing Stats: 417 words · 2 min read · ~1 pages · Grade level 13.3 · Accepted 2024-01-12 16:05:27
Key Financial Figures
- $248,000 — ns annual base compensation will be AUD $248,000. Ms. Krumeich will remain with the Co
Filing Documents
- d94385d6k.htm (6-K) — 10KB
- 0001193125-24-007502.txt ( ) — 11KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT Appointment of Director Resignation of Chief Financial Officer; Appointment of Principal Accounting Officer and Principal Financial Officer On January 8, 2024, Kazia Therapeutics Limited (the Company) received notice from Karen Krumeich of her intention to resign as the Companys Chief Financial Officer, effective immediately. Ms. Krumeichs resignation is not the result of any disagreement between Ms. Krumeich and the Company, its management or board of directors, or related to the Companys operations, policies or practices. On January 11, 2024, the Companys Board of Directors appointed Gabrielle Heaton as its Principal Accounting Officer and Principal Financial Officer, effective January 15, 2024. Ms. Heatons annual base compensation will be AUD $248,000. Ms. Krumeich will remain with the Company in an advisory role for a period of time to be mutually agreed between her and the Company to support the transition. Ms. Heaton currently serves as the Companys Vice President of Finance and Administration. She has over 20 years of commercial experience in healthcare and biotech for multinational, ASX listed and overseas companies. She has held several senior Finance positions including CFO, Quality Auditor and been responsible for Human Resources and IT. Ms. Heaton has a Bachelor of Business from the University of Technology and is a member of CPA Australia. The Company hereby incorporates by reference the information contained herein into the Companys registration statements on Form F-3 (File Nos. 333-259224 and 333-276091). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 12 January 2024